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Colorectal cancer risk is associated with biochemical markers for B-vitamin deficiency, insulin resistance and colonic inflammation,
suggesting that these three conditions are each involved in colon carcinogenesis. We expected that dietary supplements of folic acid,
n-3 fatty acids and calcium would reduce the markers and thus possibly cancer risk. We therefore randomised 98 participants, with
previous colonic polyps or intramucosal carcinomas, to a combined treatment of supplementary folic acid, fish oil and calcium
carbonate, or placebos for 28 days. Blood and faecal samples were obtained prior to and at the conclusion of the intervention and
analysed for plasma folate, homocysteine, insulin, free fatty acids, triglycerides and faecal calprotectin. In addition, plasma vitamin B12,
thiamin, glucose and C-reactive protein were assessed. Our supplemental strategy modestly affected some of the biomarkers
associated with folate metabolism and insulin resistance, but had no effect on those associated with colonic inflammation. This pilot
study demonstrates the feasibility and practicality of clinical trials aimed at reducing diet-related biochemical risk markers for colon
cancer. We suggest that long-term intervention studies with tumour-related end points should be undertaken when the intervention
agents used are found effective in short-term biochemical risk marker trials.
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Colorectal cancer risk has been related to diet and lifestyle factors
by epidemiological and animal studies over many years (World
Cancer Research Fund, 1997). Progress has been slow, however,
in defining specific dietary interventions to reduce the risk
(Greenberg et al, 1994; MacLennan et al, 1995; Baron et al, 1999;
Alberts et al, 2000; Bonithon-Kopp et al, 2000; Schatzkin et al,
2000). This may have been a consequence of the cumbersome
method that has been used to test possible interventions. The
primary approach used has been randomised controlled trials in
which the end point was the appearance of colonic polyps (Bruce
et al, 1981). These tumours take years to develop and many
subjects are needed to yield significant results. More rapid and less
expensive study designs are needed. Here, we test the feasibility of
using study end points that are biochemical risk markers for colon
cancer and are known to be affected by diet and lifestyle.
Colorectal cancer risk is associated with biochemical markers
for B-vitamin deficiency (plasma folate and homocysteine), insulin
resistance (plasma insulin, free fatty acids and triacylglycerol) and
colonic inflammation (faecal calprotectin) as shown in Table 1,
column 1. Dietary and other lifestyle factors are thought to affect
the three risk markers and then cancer risk through three separate
mechanisms, summarised in Table 1, column 2. A review of the
mechanisms suggests several approaches that could be made to
reduce the levels of the markers. Weight loss and exercise are
already known to reduce the markers of insulin resistance
(Knowler et al, 2002) and could improve the other markers as
well. However, weight loss and exercise are difficult to maintain for
the prolonged periods of time required for cancer prevention
studies, and are also difficult to apply to the general population.
Interventions based on dietary supplements are relatively more
easily applied and could be effective. Thus, supplementary folic
acid has been found to reduce elevated homocysteine; supplemen-
tary fish oil containing n-3 fatty acids, to reduce elevated insulin
and triacylglycerols; and supplementary calcium, to reduce colonic
inflammation associated with elevated levels of bile acids (Table 1,
column 3). We might thus expect that dietary supplements of
fish oil, folic acid and calcium would reduce the risk markers
for B-vitamin deficiency, insulin resistance and colonic inflam-
mation.
Herein, we describe a test for these expectations using a short-
term randomised controlled trial. In addition to the primary
measures, we measured plasma vitamin B12, since homocysteine
concentration can depend on its concentration (Standing Com-
mittee on the Scientific Evaluation of Dietary Reference Intakes,
1999), thiamin, as experimental studies suggest that thiamin
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sdeficiency can result in the formation of endogenous a-oxoalde-
hydes and the induction of colon cancer (Bruce et al, 2003), and
C-reactive protein, since it provides a more general assessment of
inflammation than faecal calprotectin and is itself associated with
colon cancer risk (Erlinger et al, 2004).
SUBJECTS AND METHODS
Participants
Participants were patients of the Gastroenterology Clinic, St
Michael’s Hospital, Toronto, with a history of previously resected
colonic adenomatous polyps or intramucosal carcinomas with no
complication for a period of 6 or more weeks. They were recruited
through a letter addressed from their physicians, a follow-up
phone call and an interview to ensure that they met the inclusion
criteria and had no treatment for underlying inflammatory bowel
disease, severe comorbidity, gastrointestinal disorder, seizure
disorder, recent use of antibiotics, use of immunosuppressive
agents, and were willing to forgo any use of calcium supplements
and any nonsteroidal anti-inflammatory agent including aspirin.
(Multivitamin use was continued and monitored throughout the
study).
The 112 participants in the study were enrolled from 8 May 2002
to 11 September 2003. This period included the period of the SARS
epidemic in Toronto that made participation difficult for many
potential subjects. In all, 98 participants comprised the study.
Study protocol
The Review Board of St Michael’s Hospital and the Ethical Review
Board of the University of Toronto approved the study protocol.
It followed a randomised placebo-controlled design. After the
recruitment letter and phone call, interested participants provided
an informed consent. They were assigned a study number, were
instructed regarding collecting faecal samples and on maintaining
a 3-day diet record and abdominal symptoms book (reviewed
immediately prior to and at the conclusion of the intervention).
A blood sample was obtained and the participants, after they
were confirmed to have a normal vitamin B12, were randomised by
tumour status (adenoma or carcinoma) to the treatment or control
(placebo) groups by the research pharmacy department using a
code provided by the statistician. Of the 98 participants, 50 were
randomised to the treatment arm, and 48 to the control arm. A
faecal sample was collected and mailed to the laboratory, the
supplements begun and blood and faecal samples were collected
again 28 days later. The participants were asked to continue their
usual use of multivitamins and diet through the intervention
period, but to discontinue any use of aspirin or calcium
supplements from the time of recruitment to the conclusion of
Table 1 Biochemical markers associated with colorectal cancer risk, possible mechanisms relating diet, marker and cancer, and dietary interventions that
were suggested by the mechanism and were evaluated in this pilot intervention trial
Risk factor/biochemical markers
Possible mechanisms relating diet, risk
marker and colon cancer This pilot study intervention
(1) B-vitamin deficiency/plasma homocysteine, folate
(Giovannucci, 2002; Martinez et al, 2004)
Diet marginally deficient in folic acid decreases plasma
folate and intracellular colonic folate (Kim et al, 1998)
and increases the concentration of plasma
homocysteine. Homocysteine is thus an accurate
inverse indicator of folate status (Standing Committee
on the Scientific Evaluation of Dietary Reference
Intakes, 1999). Low folate status can result in
increased chromosome instability, DNA damage,
impaired repair, aberrant DNA methylation and point
mutations (Cravo et al, 1994; Fenech et al, 1997; Kim,
1999). These initiate colon carcinogenesis
Folic acid (Kim et al, 1996; Newmark et al, 2001;
Konings et al, 2002)
(2) Insulin resistance/plasma insulin, free fatty acids and
triacylglycerol (McKeown-Eyssen, 1994; Giovannucci,
1995; Kim, 1998)
Dietary factors including a hypercaloric diet with
refined sugars, increased saturated fat, and reduced n-
3 fatty acids, together with reduced energy
expenditure, increase the accumulation of energy
substrates in the body and lead to insulin resistance
(Storlien et al, 1991; Tran et al, 1996, 2003;
Koohestani et al, 1998; Bruce et al, 2000; Kaaks et al,
2000). Insulin resistance is a state of decreased insulin
action that is usually accompanied by increased
concentrations of: insulin (due to compensatory
hypersecretion of insulin), free fatty acid (FFA, due to
the impaired antilipolytic action of insulin) and
triacylglycerols (TG, derived from the released FFA)
(DeFronzo and Ferrannini, 1991). The increased
insulin and/or availability of energy provides a stimulus
for proliferation and promotion of colon tumours.
Fish oil with long chain n-3 fatty acids (Paulsen et al,
1998; Bartsch et al, 1999; Stark et al, 2000)
3) Colonic inflammation/faecal calprotectin (Kristinsson
et al, 1998; Kronborg et al, 2000)
Diets deficient in calcium lead to an exposure of the
colon to free bile and fatty acids, and to an
inflammatory response (Wargovich et al, 1983;
Newmark et al, 1984). The colonic inflammation
increases initiation and promotion of colon cancer
(Gillen et al, 1994; Biasco et al, 1995; Kristinsson et al,
1999; Okayasu et al, 2002).
Calcium carbonate (Newmark et al, 1984; Wargovich
et al, 1990; Baron et al, 1999; Bonithon-Kopp et al,
2000)
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sthe study. (This was confirmed by a review of their diet and
supplement records through the intervention period.) Compliance
was assessed by a count of the capsules and tablets returned.
Compliance was good with a presumed consumption of 94%
(range 53–100%) of the capsules and tablets. Five of the
participants, all in the treatment group, reported increased
constipation (P¼0.056).
Analytic methods
Blood samples were obtained in the morning 2.0h postprandial,
with breakfast consisting of two Kellogg Pop Tarts
s, providing
74g carbohydrate, primarily as starch, and a noncaloric drink.
Blood glucose, vitamin B12 and homocysteine were assessed by the
clinical laboratory at St Michael’s Hospital. (reference ranges for
nonfasting glucose were 4.0–7.8mmoll
 1;B 12, 110–630pmoll
 1;
homocysteine, 4–15mmoll
 1). hsC-reactive protein was deter-
mined by the Lipid Research Laboratory (0.00–3.80mgl
 1),
triacylglycerols (Roche Diagnostics, Hoffman-La Roche Ltd, Laval,
Canada), free fatty acids (NEFA C Assay kit, Wako, Neuss,
Germany) and insulin (Coat-A-Count Insulin Assay kit, Diagnostic
Products Corporation (DPG), Los Angeles, CA, USA) by one of the
investigators (AG), and folate was determined by microbiological
assay (Kim et al, 2001). Thiamin was assessed at the time of entry
to the study by the Reference Laboratory, St Joseph’s Hospital,
London, Ontario, Canada. Faecal sample specimens were collected
by the participant on a small spatula, placed in a doubly enclosed
plastic bottle and mailed to the laboratory where they were stored
at –801C. The faecal calprotectin concentrations were determined
as described by Røseth et al (1992), using the same reagents
provided by MK Fagerhol (reference range 0–49mgl
 1). Testing
of 25 faecal samples, express-mailed from up to 30km from the
laboratory, showed that the measurements were not affected by the
typical 24h period spent in mail delivery (data not shown). Before
and after samples were assayed at the same time for folate, insulin,
FFA, triacylglycerol and faecal calprotectin.
Intervention agents
Folic acid, 1mg three times a day, was provided as a commercial
product donated by Jamieson Vitamins (Windsor, Ontario,
Canada). The placebo was an identical-appearing cellulose–
sucrose tablet provided by the company. Fish oil concentrate, 2g
three times a day, was provided as MEG-3t brand omega-3 fish oil
ingredients (1000mg capsules containing approximately 300mg
eicosopentaenoic acid, 200mg docosahexaenoic acid and 42mg
mixed natural tocopherols per capsule) donated by Ocean
Nutrition Canada Ltd (Dartmouth, Nova Scotia, Canada). The
placebo agent was olive oil (1000mg capsule, Ocean Nutrition
Canada Ltd). Calcium, 500mg three times a day, was provided as
1250mg tablets of calcium carbonate donated by Consumer
Products, GlaxoSmithKline (Oakville, Ontario, Canada). The
placebo was an identical-appearing cellulose–sucrose tablet
provided by the company.
The dosages used were based on problem-free usage in previous
clinical trials (e.g. Baron et al, 1999, Bonithon-Kopp et al, 2000;
Stark et al, 2000; Kim et al, 2001). The period of intervention (28
days) was chosen so as to allow sufficient time for biochemical
measures representing the major environmental exposures to
stabilise. It would, of course, be too short a period to observe
changes in colonic pathology such as of aberrant crypt foci (ACF)
or of colonic polyps.
Statistical analysis
Participants were randomised to the treatment or placebo arms of
the study, stratified by tumour type (adenoma or carcinoma), in
blocks of eight participants. Comparisons, based on the log scale
where appropriate, were evaluated with Student’s t-test, Po0.05
being considered significant. Correlation coefficients were taken as
significant for values of Po0.05, which for n¼98 corresponds to a
r-value of 0.20. The sample size for the trial (n¼98) was calculated
to provide significance and power (a¼0.05 and b¼0.8) sufficient
to identify a two-fold reduction of faecal calprotectin based on
Norwegian population screening data provided by MK Fagerhol,
Oslo (personal communication). Subanalyses of the trial results
were made with adenoma cases only and separately for males and
females. Evaluation of the treatment effect after adjusting for prior
use of ASA and Ca was carried out using a regression analysis,
explanatory variables being prior use of ASA, prior use of Ca, their
interaction and treatment. Similarly, for the response variables
measuring change, evaluation of the treatment effect after
adjusting for baseline values was carried out with a regression
analysis, explanatory variables being baseline and treatment. The
effect of treatment was also assessed after adjusting for weight gain
and for the size of the tumour and its pathological category (villous
or tubular adenoma).
RESULTS
Initial measurements
The characteristics of the subjects prior to randomisation and the
intervention are shown in Table 2. Of the 98 subjects, 67 were
males with a mean age of 62.1 years (range 49–80 years) and 31
were females with a mean age of 59.8 years (44–75 years). In all, 78
patients had a diagnosis of tubular adenoma, 14 of tubulovillous or
villous adenoma and six of adenocarcinoma confined to the
mucosa. The mean number of lesions per patient was 1.28 (1–3)
and the mean size of the largest lesions was 5.85mm (2–20). The
mean time from the colonoscopy to first clinic visit for the study
was 149 days (99–329 days). Some variables showed substantial
Table 2 Characteristics of the participants at entry to the study
Characteristic No. Mean (s.d.)
Age (years) 98 61.4 (8.7)
Males
Height (m) 67 1.78 (0.08)
Weight (kg) 67 85.4 (14.6)
BMI (kgm
 2) 67 27.0 (3.6)
Females
Height (m) 31 1.65 (0.06)
Weight (kg) 31 67.4 (11.0)
BMI (kgm
 2) 31 24.6 (3.8)
Tumour characteristics
Number 98 1.28 (0.55)
Size (mm) 98 5.85 (4.84)
Tubular adenoma 78
Villous adenoma 14
Mucosal adenocarcinoma 6
Biochemical measures
Folate (nmoll
 1) 94 58.0 (37.9)
B12 (pmoll
 1) 98 287 (119)
Thiamin (nmoll
 1) 57 58.7 (32.9)
Homocysteine (mmoll
 1) 97 8.6 (3.2)
Insulin (pmoll
 1) 96 199 (156)
Triacylglycerols (mmoll
 1) 95 2.0 (1.1)
FFA (mEql
 1) 96 335 (206)
Glucose (mmoll
 1) 98 5.5 (1.5)
Faecal calprotectin (mgl
 1) 98 15.4 (22.4)
C-reative protein (mgl
 1) 98 2.4 (3.5)
s.d.¼standard deviation; BMI¼body mass index; FFA¼free fatty acid.
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sskewness and were presented in subsequent analyses as geometric
means after conversion from the log to the original scale.
The effect of prior use of multivitamins, calcium supplements
and aspirin on the initial biochemical measurements is shown in
Table 3. (Use of aspirin and calcium was discontinued prior to the
intervention.) Nearly one-half of the individuals stated that they
took the multivitamins including the B-vitamins. They had a 53%
higher concentration of vitamin B12 and 23% lower homocysteine
and possibly lower free fatty acids. Almost one-quarter had
previously used calcium supplements, in all cases at a lower dosage
than that used in this intervention. They had 30% higher vitamin
B12 and perhaps lower homocysteine, possibly because these
individuals were more likely to take multivitamins as well (15 of 24
vs 31 of 74, P¼0.10). A smaller fraction had previously used
aspirin, intermittently or at low dose (average o100mgday
 1).
Prior use of aspirin was possibly associated with an increase in free
fatty acids (P¼0.059).
The initial biochemical measurements also showed some
interesting correlations. The clearest correlations were between
glucose and insulin, triacylglycerols and free fatty acids, vitamin
B12 and thiamin, and body mass index (BMI) and C-reactive
protein (r¼0.52, 0.46, 0.36 and 0.32, respectively). Vitamin B12
was associated with lower homocysteine, and thiamin with lower
insulin (r¼ 0.28 and  0.24, respectively). There was no
association between faecal calprotectin and C-reactive protein
(r¼0.13). Similar correlations were observed at the conclusion of
the study, although in addition, significant correlations were
observed between BMI and free fatty acids, triglycerides and
insulin.
Intervention measures
The mean values for the treated and control groups at entry to the
study are shown in Table 4 (data columns 1 and 2). Randomisation
resulted in similar values for most of the measures, but differences
were noted for BMI and C-reactive protein. The males in the
control group had a higher average BMI and C-reactive protein
than those in the treated group. Use of multivitamins and prior use
of calcium and aspirin was distributed evenly between the treated
and control groups (data not shown).
The mean values for the groups at the conclusion of the 28-day
intervention are shown in Table 4 (columns 4 and 5). The first
t-test P-value is for the difference between the changes in values
for the control and treated groups; the second has been adjusted
for differences in the baseline (initial values). Analysis of the data
excluding participants with a history of colon cancer provided
essentially the same results, as did analysis adjusting for the prior
use of ASA and calcium, for gender, for number and pathology of
the tumours, and for weight gain.
Men on the treatment allocation increased weight and BMI more
than the men allocated to placebo, a difference that approached
statistical significance (P¼0.051 and 0.088, respectively). There
was no equivalent effect of treatment with the female participants.
Subjects on the treatment allocation had a 3% decrease in
homocysteine concentration, while for those in the control
allocation had a 7% increase, a difference that was not significant
(P¼0.096); for folate, the respective changes were a 123% increase
and a 8% increase (P¼2 10
 6); and for vitamin B12, a 11%
increase and a 7% decrease (P¼0.0044). For insulin, subjects on
the treatment allocation had a 27% increase, while those on the
control allocation had a 18% increase, a difference that was not
significant; for FFA, the respective changes were a 18% reduction
and 10% increase (P¼0.013); for triglycerides, a 15% reduction
and a 1% decrease (P¼0.11); and glucose concentrations were
unaffected by the intervention. For faecal calprotectin, subjects on
the treatment allocation had a 15% reduction, while those on the
control allocation had a 6% decrease, a difference that was not
significant; for C-reactive protein, the respective changes were a
35% increase and a 17% decrease, a difference that approached
statistical significance (P¼0.12).
DISCUSSION
The primary method that has been used to evaluate dietary
measures for their effect on colon cancer risk has been randomised
controlled trials with end points based on the recurrence of colonic
polyps. Polyp trials take a long time and large resources to do.
They assess the effect of an intervention on only a limited portion
of the carcinogenesis process. Study methods that can be assessed
more quickly and that evaluate effects over a longer period of the
carcinogenesis process are desirable. Several other types of end
points are possible: (1) end points based directly on changes in the
colon directly involved in the neoplastic process leading to polyps
and cancers (e.g. ACF number and size, genetic markers of the
carcinogenesis process); (2) end points reflecting dietary con-
sumption of nutrients related to colon carcinogenesis (e.g.
B-vitamin measures); (3) end points not in the colon that reflect
systemic physiological changes thought to be related to cancer risk
(e.g. insulin resistance); and (4) end points indicating damage to
the colon that may lead indirectly to increased cancer risk but are
not directly involved in the carcinogenesis (e.g. colonic inflamma-
tion, epithelial permeability, oxidative stress). The present study
further demonstrates the feasibility of an end point of type (2) and
demonstrates the feasibility and practicality of clinical trials based
on end points of types (3) and (4).
We used three end points – B-vitamin deficiency, insulin
resistance and colonic inflammation – in this pilot study. The
Table 3 Use of multivitamin and calcium supplements and aspirin at entry to the intervention, and corresponding biochemical measures
Multivitamins Calcium Aspirin
No Yes P-value No Yes P-value No Yes P-value
Number 52 46 74 24 79 19
Folate (nmoll
 1)
a 40.8 47.0 0.40 42.5 47.5 0.57 43.5 44.3 0.89
Homocysteine (mmoll
 1) 9.69 7.50 0.010 9.11 7.25 0.056 8.63 8.73 0.93
B12 (pmoll
 1) 214 328 6 10
 7 249 324 0.0063 267 268 0.99
Thiamin (nmoll
 1) 56.4 60.6 0.44 57.2 62.7 0.36 58.0 64.0 0.46
Insulin (pmoll
 1)
a 161 145 0.49 160 136 0.35 150 170 0.56
FFA (mEql
 1)
a 319 263 0.063 306 252 0.11 279 370 0.059
Triacylglycerols (mmoll
 1)
a 1.71 1.67 0.85 1.70 1.66 0.83 1.64 2.0 0.19
Glucose (mmoll
 1) 5.36 5.63 0.37 5.41 5.72 0.36 5.46 5.61 0.72
Faecal calprotectin (mgl
 1)
a 6.8 8.0 0.51 8.0 5.7 0.26 7.9 4.9 0.18
C-reactive protein (mgl
 1)
a 1.43 1.26 0.54 1.34 1.38 0.90 1.36 1.30 0.88
FFA¼free fatty acid.
aDenotes measures for which geometric means were used in the calculation of averages and P-values (see Statistical methods).
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together, or placebo tablets and capsules. The intervention
increased folate as expected, modestly reduced homocysteine and
two markers of insulin resistance, free fatty acids and triglycerides,
but did not affect insulin, colonic inflammation, as assessed by
faecal calprotectin, or generalised inflammation, as assessed by
C-reactive protein. Studies using three end points are clearly
feasible and practical. Thus, it appears possible to refine and
optimise the interventions to reduce the risk markers.
B-vitamin deficiency
Folic acid reduced homocysteine concentration with respect to the
control group to a small, although not statistically significant,
degree. This is in contrast with an earlier study that observed a
decrease of 35% with a 5mgday
 1 folic acid supplementation (Kim
et al, 2001). Our participants, at baseline however, had no evidence
of folate deficiency and, in fact, had generally higher concentra-
tions of folate compared to earlier studies (Selhub et al, 1993,
1999). This is presumably a result of the recent fortification of
cereal grain products with folic acid, which would explain the
small reduction of homocysteine observed here using large
increases of supplementary folic acid, as the effect of increased
folic acid tends to saturate at high intakes of folate (Ray et al,
2000).
Homocysteine concentration and methyl donor status are
known to depend on intake of vitamins B6 and B12, in addition
to folic acid (Standing Committee on the Scientific Evaluation of
Dietary Reference Intakes, 1999). Both of these vitamins may be
marginally deficient in our participants. This suggestion is
supported by our observation that participants of our study, who
took multivitamin supplements containing these vitamins, had
significantly lower homocysteine than those that did not.
Homocysteine was also significantly negatively associated with
vitamin B12, at entry to the study. In addition, deficiency of
vitamin B6 alone appears important in animal studies of colon
carcinogenesis (Matsubara et al, 2003). Clearly, future studies
should test the effects of vitamins B6 and B12 as well as folic acid on
this risk marker.
We also measured plasma thiamin concentrations in this study
because we had found previously that the colons of rats fed diets
marginally deficient in thiamin had an increased number of ACF,
putative precursor lesions of colon cancers, and because we had
suggested that thiamin deficiency could be involved in human
colon carcinogenesis (Bruce et al, 2003). In this study, we found
that the plasma thiamin concentrations of our subjects were
generally low (58.7þ32.9nmoll
 1 (s.d.)) compared to the
reference range (54–78nmoll
 1).
Insulin resistance
Plasma free fatty acids and possibly triacylglycerols were reduced
by the intervention, although insulin was not. Animal models have
shown an effect of n-3 fatty acids on insulin resistance (Storlien
et al, 2000) and fish oil has been previously found to decrease
triacylglycerols (Paulsen et al, 1998; Lovegrove et al, 2004). The
apparent discrepancy between the results of these studies could be
a consequence of the control fat used in our study, namely olive
oil, which may itself have a small protective effect. It could also
have been a consequence of how we collected the blood samples,
that is, 2h after the breakfast eaten at home, without a restriction
on physical activity. Our expectation, based on animal studies, was
that measurements of insulin taken in a defined postprandial
period would correlate closely with the more direct measures of
insulin resistance (Tran et al, 2003). This may not be the case when
the subjects’ activities are not limited as they are in strict metabolic
studies. Thus, there may well be a place for n-3 fatty acids in the
prevention of insulin resistance. Plasma insulin concentrations in
the study were correlated with reduced concentrations of thiamin.
This suggests that thiamin deficiency can induce insulin resistance,
Table 4 Initial and final weights, BMI and biochemical measures of participants on the 28-day intervention
Initial values Final values Change of values
Control Treated t-test Control Treated t-test t-test
Mean Mean P-value Mean Mean P-value P-value
adjusted
a
Age (years) 60.7 62.0 0.45
Males
Height (m) 1.77 1.78 0.53
Weight (kg) 87.6 83.4 0.16 88.1 84.6 0.064 0.051
BMI (kgm
 2) 27.9 26.2 0.04 28.0 26.6 0.084 0.088
Females
Height (m) 1.65 1.66 0.53
Weight (kg) 65.5 69.5 0.31 65.9 70.3 0.51 0.46
BMI (kgm
 2) 24.1 25.2 0.40 24.2 25.5 0.57 0.49
Biochemical measures
Homocysteine (mmoll
 1) 8.42 8.88 0.59 9.04 8.64 0.082 0.096
Folate (nmoll
 1)
b 44.0 43.3 0.93 47.7 96.4 1.2 10
 6 2 10
 6
B12 (pmoll
 1) 289 247 0.09 268 273 0.0033 0.0044
Thiamin (nmoll
 1) 61.8 55.3 0.23 NA NA
Insulin (pmoll
 1)
b 152 154 0.92 180 195 0.66 0.63
FFA (mEql
 1)
b 277 305 0.35 306 249 0.008 0.013
Triacylglycerols (mmoll
 1)
b 1.61 1.77 0.41 1.60 1.50 0.073 0.11
Glucose (mmoll
 1) 5.64 5.33 0.29 5.82 5.50 0.96 0.73
Faecal calprotectin (mgl
 1)
b 7.01 7.67 0.73 7.41 6.52 0.41 0.46
C-reactive protein (mgl
 1)
b 1.77 1.04 0.007 1.48 1.4 0.012 0.12
BMI¼body mass index; FFA¼free fatty acid; NA¼not applicable.
aP-values for difference between control and treated groups change in values, adjusted for differences at
baseline (initial values). Adjustments omitting cancer cases, or adjusting for initial weight, polyp size and pathology or previous use of calcium supplements or ASA had negligible
effects on P-values.
bDenotes measures for which geometric means were used in the calculation of averages and P-values (see Statistical methods).
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sperhaps through an effect on oxidative stress (Bakker et al, 1997,
1998; Shangari et al, 2003). Perhaps, interventions with n-3 fatty
acids together with thiamin would be more effective than the fatty
acids alone and would provide a benefit approaching that of weight
loss and exercise (Knowler et al, 2002).
Colonic inflammation
The calcium intervention did not appear to significantly affect
colonic inflammation as assessed by faecal calprotectin. Our initial
expectation, that calcium would reduce colonic inflammation, was
based on: (1) the observation that calcium reduces the appearance
of new colonic polyps (Baron et al, 1999; Bonithon-Kopp et al,
2000), (2) the expectation that bile and fatty acids in the faecal
stream may be toxic and produce inflammation (Wargovich et al,
1983), and (3) the expectation that this toxicity would be reduced
by increased calcium salts (Newmark et al, 1984). In addition, we
might anticipate that the intervention with n-3 fatty acids with fish
oil would inhibit the formation of arachidonic acid and
inflammatory mediator production (James et al, 2000). Perhaps,
the inflammation assessed by the calprotectin, measuring as it
does migration of granulocytes into the faecal stream (Røseth et al,
1992), is not a consequence of toxic bile acids or prostaglandins. It
may instead be a result of an ongoing colon carcinogenesis process
in this older population. Experimental animals treated with colon
carcinogens show a loss of epithelial integrity with ACF formation
and an associated increase in faecal granulocyte marker protein
(GMP) (Kristinsson et al, 1999; Soler et al, 1999). We have found
that many patients in a similar study population have ACF in their
distal colon and rectum (unpublished observation) and suspect
that colonic ACF are associated with colon cancer risk. This then
would explain the association of faecal calprotectin with known
dietary risk factors for colon cancer (Poullis et al, 2004). However,
colonic inflammation, as assessed by faecal GMP in rodents, can
be reduced by the demulcent, polyethylene glycol (PEG 8000)
(Karlsson et al, 2005). This agent also reduces experimental colon
carcinogenesis to a remarkable degree (Corpet and Tache, 2002).
Although some oligosaccharides are known demulcents, no effort
appears to have been made to identify such an effect with the use
of faecal GMP, which could provide a simple assay for agents with
possible protective effects.
Plasma C-reactive protein was also not reduced by the
intervention and there was no association between the two
markers of colonic and of general inflammation. C-reactive
protein was associated with BMI in this study and has been
associated with vitamin B6 concentrations in earlier reports (see,
for instance, Friso et al, 2001; Connelly et al, 2003).
The reader will have noted the similarity between the
biochemical risk markers for colon cancer and the risk factors
for other chronic noncommunicable diseases such as diabetes,
hypertension and cardiovascular disease. Insulin resistance is a
well-known risk factor for all three, homocysteinaemia is a risk
factor for cardiovascular disease (e.g. Whincup et al, 1999) and the
pathogenesis of all may involve inflammation (e.g. Ridker et al,
2004). These similarities suggest that the underlying aetiological
mechanisms may overlap in some way. Certainly, the dietary and
lifestyle risk factors for colorectal cancer and insulin resistance are
similar (McKeown-Eyssen, 1994; Giovannucci, 1995). There has
also been a striking association of colon pathology (colonic
polyps) with cardiovascular pathology (coronary artery athero-
sclerotic plaques) observed in autopsies of Japanese migrants to
Hawaii (Stemmermann et al, 1986). These similarities suggest that
future interventions for the prevention of colon cancer might
benefit from attention to, and perhaps coordination with,
prevention studies directed toward these other noncommunicable
diseases. This would be especially important should it become
necessary to use more stringent lifestyle interventions such as
those used in the Diabetes Prevention Trial (Knowler et al, 2002).
Finally, we note that a refined and optimised intervention to
reduce the biochemical risk markers for colon cancer must still be
evaluated for its efficacy at reducing the development of cancer
itself. This is because we cannot be certain that the risk factors we
have chosen are the only, or even the major, ones involved in the
development of cancer. This may be difficult. Certainly, an
optimised intervention could be tested for its ability to reduce
polyp recurrences. Polyp studies provide clinically interesting and
useful results; however, they assess only a portion of colon
carcinogenesis, the effect of interventions on the growth of
microadenoma (or large ACF) to macroscopic tumours. Interven-
tions based on biochemical risk markers may have effects on the
earlier and longer period of carcinogenesis in which genetic,
physiologic and pathologic events result in the appearance and
growth of the early precursor lesions. Evaluations of interventions
through this period could be of greater public health importance,
although methods for assessing the effect of diet and lifestyle
factors on this earlier period have only recently been assessed, with
an end point of type (1) above (e.g. Moxon et al, 2005; Rudolf et al,
2005).
In summary, this pilot study demonstrates the feasibility and
practicality of clinical trials aimed at developing interventions to
reduce biochemical markers associated with colon cancer risk. The
intervention tested in this study was not very effective at reducing
the markers. However, a review of the results suggests several
possible improvements: (1) vitamins B6 and B12 could be added to
folic acid for an increase of methyl donor status, a reduction of
homocysteine and possibly a reduction of C-reactive protein. (2)
Thiamin could be added to n-3 fatty acids for a reduction of
markers of insulin resistance. (3) Animal studies could be initiated
to identify dietary components that act as colonic demulcents and
reduce colonic inflammation. These possibilities make us opti-
mistic that combinations of food additives will be identified that
significantly reduce colon cancer risk markers and may subse-
quently be shown to reduce the process of carcinogenesis and
cancer incidence.
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